Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Luceome Biotechnologies LLC
Profile last edited on: 5/15/2018      CAGE: 50Z38      UEI: PTPNMPNRP5R1

Business Identifier: Drug discovery by use of kinase assay technology
Year Founded
2007
First Award
2009
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1665 East 18th Street Suite 106
Tucson, AZ 85719
   (520) 495-0161
   info@luceome.com
   www.luceome.com
Location: Single
Congr. District: 07
County: Pima

Public Profile

Luceome Biotechnologies enables drug discovery by leveraging its assay technology for identification of drugs against kinases. The firm currently uses its patented split-protein based cell-free assay technology for kinase profiling of small molecule inhibitors. Luceome provides unique assay solutions (KinaseSeeker and KinaseLite) to clients for meeting their selectivity profiling needs as well as for the development of assays against specific targets. Luceome's assays are based on a technology platform that utilizes luciferase fragment complementation. The resulting luminescence detection is sensitive with low background interference, allowing identification of target and off-target effects of drug candidates.

Extent of SBIR involvement

User Avatar
Phase I Awards
9
Phase II Awards
4
Conversion Rate
44.44%
Phase I Dollars
$2,336,099
Phase II Dollars
$5,703,073
Total Awarded
$8,039,172

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,225,000
Project Title: Enabling Toxoplasma Gondii Kinome Directed Drug Discovery
2022 1 NIH $240,429
Project Title: Split-luciferase Epigenetic Assays for Drug Discovery
2021 2 NIH $1,756,241
Project Title: Kinase Targeted Antimalarial Agents
2018 2 NIH $1,408,440
Project Title: Tools for Accelerating R&D for Historically Understudied Protein Kinases
2017 2 NIH $1,736,286
Project Title: Kinome-Wide Cell-Based Assays

Key People / Management

  Reena Zutshi -- Founder, President and CEO

  Indraneel Ghosh -- Chief Scientific Officer and Co-Founder

  Frank Kwarcinski -- Scientist

  Jennifer Marshall -- CFO and Business Development

  Karla Camacho Soto -- Scientist

Company News

There are no news available.